Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of KP104 in IgA nephropathy and C3 glomerulopathy
CTR20223383Phase 2Active
- Sponsor
- Kira Pharmaceuticals
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KP104 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (5 arms), sponsored by Kira Pharmaceuticals. Primary endpoint: Percent change from baseline in 24-hour urine protein-to-creatinine ratio. Started Jun 2026; status: active.
02
Drugs
KP104
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on CTR20223383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223383.